Molecular targeted therapy for renal cell carcinoma
Renal cell carcinoma (RCC) accounts for approximately 2% of all cancer cases worldwide. Metastatic disease is often present at the time of diagnosis of RCC and its poor response to chemotherapy and radiotherapy causes poor prognosis. Immunotherapy is relatively effective for RCC, but the response ra...
| Publié dans: | Hinyokika kiyo. Acta urologica Japonica. - 1962. - 54(2008), 1 vom: 08. Jan., Seite 53-6 |
|---|---|
| Auteur principal: | |
| Autres auteurs: | , , , |
| Format: | Article |
| Langue: | Japanese |
| Publié: |
2008
|
| Accès à la collection: | Hinyokika kiyo. Acta urologica Japonica |
| Sujets: | Journal Article Review Antineoplastic Agents Apoptosis Regulatory Proteins Benzenesulfonates DIABLO protein, human Indoles Intracellular Signaling Peptides and Proteins Liposomes Mitochondrial Proteins plus... |
| Résumé: | Renal cell carcinoma (RCC) accounts for approximately 2% of all cancer cases worldwide. Metastatic disease is often present at the time of diagnosis of RCC and its poor response to chemotherapy and radiotherapy causes poor prognosis. Immunotherapy is relatively effective for RCC, but the response rate is approximately 15-20%. Therefore, new therapeutic approaches are necessary for these patients with metastatic RCC. Recently, the mechanisms responsible for the growth of RCC have been clarified, and molecular targeted therapy has been developed. In this paper, we review the new molecular targeted therapeutic agents effective for RCC |
|---|---|
| Description: | Date Completed 01.04.2008 Date Revised 10.12.2019 published: Print Citation Status MEDLINE |
| ISSN: | 0018-1994 |